α-Synuclein oligomers form by secondary nucleation.

Area of Science:

• Biochemistry
• Neuroscience
• Molecular Biology

Background:

• Oligomeric species of α-synuclein are key contributors to Parkinson's disease (PD) pathogenesis.
• Understanding the formation and role of these oligomers is crucial for developing effective PD therapeutics.
• The precise mechanisms driving α-synuclein aggregation and oligomer generation remain largely undefined.

Purpose of the Study:

• To elucidate the primary mechanism responsible for the formation of toxic α-synuclein oligomers.
• To investigate the role of secondary nucleation versus primary nucleation in aggregate formation.
• To characterize α-synuclein aggregation under physiologically relevant conditions (neutral pH, no membranes).

Main Methods:

• Utilized a combination of single-molecule and bulk-level techniques.
• Studied α-synuclein aggregation at physiological pH and ionic strength.
• Investigated the impact of agitation on the aggregation process.

Main Results:

• α-synuclein aggregation proceeds via secondary nucleation, not simple primary nucleation, at physiological pH.
• Agitation significantly enhances the rate of secondary nucleation.
• Existing α-synuclein fibrils act as surfaces for secondary nucleation, generating the majority of oligomers.
• Oligomer formation occurs predominantly on fibril surfaces rather than directly from monomers.

Conclusions:

• Secondary nucleation is identified as the dominant pathway for generating toxic α-synuclein oligomers.
• This process is the principal mechanism driving α-synuclein aggregate formation in vitro.
• The findings occur under conditions relevant to the cellular cytosol, providing critical insights into PD mechanisms.